Search

Your search keyword '"MESH: Antiretroviral Therapy, Highly Active"' showing total 2 results
Start Over Descriptor "MESH: Antiretroviral Therapy, Highly Active" Publisher springer science and business media llc
2 results on '"MESH: Antiretroviral Therapy, Highly Active"'

1. Impact of age-related comorbidities on five-year overall mortality among elderly HIV-infected patients in the late HAART era — Role of chronic renal disease

Author

Maxime HENTZIEN, Dramé, M., Allavena, C., Jacomet, C., Valantin, A., André Cabié, Cuzin, L., Rey, D., Pugliese, P., Bani-Sadr, F., Hentzien, F., Dramé, D., Allavena, A., Centre Hospitalier Universitaire de Reims (CHU Reims), Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service des Maladies Infectieuses et Tropicales [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de Maladies Infectieuses et Tropicales [Fort-de-France, Martinique], CHU de la Martinique [Fort de France]-Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France]-Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Nouvel Hôpital Civil de Strasbourg, Service d'infectiologie [CHU Nice], Centre Hospitalier Universitaire de Nice (CHU Nice), IER - Institut d'Economie Rurale (IER), IER, Department of Genetics, Biology and Biochemistry, University of Turin, Service de Médecine interne, Maladies Infectieuses et Immunologie Clinique [Reims], Vieillissement, Fragilité (VIEFRA - EA 3797), Université de Reims Champagne-Ardenne (URCA), Service des maladies infectieuses [Clermont-Ferrand], CHU Clermont-Ferrand, Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles et de la Guyane (UAG), and CHU Strasbourg

Subjects
Male, Aging, Medicine (miscellaneous), HIV Infections, MESH: Comorbidity, Comorbidity, MESH: Antiretroviral Therapy, Highly Active, Cohort Studies, surgery, MESH: Proportional Hazards Models, MESH: Cause of Death, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Antiretroviral Therapy, Highly Active, Cause of Death, Neoplasms, Prevalence, MESH: Aging, MESH: Neoplasms, Prospective Studies, 030212 general & internal medicine, MESH: Anti-HIV Agents, Prospective cohort study, MESH: Cohort Studies, ComputingMilieux_MISCELLANEOUS, MESH: Aged, 2. Zero hunger, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, MESH: Middle Aged, Nutrition and Dietetics, Mortality rate, Hazard ratio, MESH: HIV Infections, Hepatitis C, Middle Aged, Hepatitis B, 3. Good health, Cardiovascular Diseases, MESH: Fibrosis, Cohort, Female, 030211 gastroenterology & hepatology, France, Cohort study, medicine.medical_specialty, MESH: Diabetes Mellitus, Anti-HIV Agents, MESH: Renal Insufficiency, Chronic, valves, 03 medical and health sciences, Internal medicine, Diabetes Mellitus, medicine, Humans, Renal Insufficiency, Chronic, Intensive care medicine, MESH: Prevalence, Aged, Proportional Hazards Models, MESH: Hepatitis C, MESH: Humans, business.industry, MESH: Cardiovascular Diseases, medicine.disease, Fibrosis, mortality, infection, MESH: Male, MESH: Prospective Studies, MESH: France, prognosis, Geriatrics and Gerontology, business, MESH: Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; To identify main prognostic factors for 5-year mortality among age-related comorbidities (ARCs) in older people living with HIV (PLHIV).; A prospective, multicentre cohort study with a 5-year follow-up period in the late HAART era (from January 2008 to December 2012).; The Dat'AIDS cohort involving 12 French hospitals.; All actively followed HIV-1 infected patients aged 60 or older.; The study endpoint was all-cause five-year mortality. The following ARCs were considered: chronic renal disease, cardiovascular diseases, cancer, chronic pulmonary disease, cirrhosis, diabetes and nutritional status. Hepatitis C (HCV), hepatitis B (HBV) co-infection and sociodemographic characteristics were also evaluated. Cox's Proportional Hazards model was used for multivariate analysis.; Among 1415 PLHIV aged 60 or more patients included, mean age was 66±5.5 years; 154 died (mortality rate 2.47/100 patient-years). The most prevalent ARCs were chronic renal disease (20.1%), diabetes (14.2%) and cardiovascular diseases (12.2%). By multivariate analysis, chronic renal disease (adjusted hazard ratio (aHR)=2.25; 95% confidence interval (CI) [1.58-2.21]; p

Published
2015

2. Population pharmacokinetic analysisof lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART

Author

Panhard, Xavière, Legrand, Mayeule, Taburet, Anne-Marie, Diquet, Bertrand, Goujard, Cécile, Mentré, France, Anrs 102 Study Group, Cophar 1, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Département d'épidémiologie, biostatistique et recherche clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de pharmacie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Département de Pharmacologie-Toxicologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de médecine interne et maladies infectieuses, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Comets, Emmanuelle

Subjects
Male, MESH: Drug Interactions, HIV Infections, Indinavir, Pharmacology, 030226 pharmacology & pharmacy, MESH: Antiretroviral Therapy, Highly Active, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Drug Interactions, Tissue Distribution, Pharmacology (medical), Population pharmacokinetics, MESH: Anti-HIV Agents, [INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM], MESH: Aged, Volume of distribution, 0303 health sciences, education.field_of_study, [SDV.BIBS] Life Sciences [q-bio]/Quantitative Methods [q-bio.QM], Nelfinavir, MESH: Middle Aged, Stavudine, MESH: Zidovudine, Lamivudine, MESH: HIV Infections, General Medicine, Middle Aged, [SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM], 3. Good health, Reverse Transcriptase Inhibitors, Nucleoside analogs, Female, Zidovudine, MESH: Lamivudine, medicine.drug, Adult, Anti-HIV Agents, MESH: Nelfinavir, Population, MESH: Stavudine, Biology, Models, Biological, Article, 03 medical and health sciences, Pharmacokinetics, medicine, Humans, Drug-drug interactions, MESH: Tissue Distribution, education, Aged, MESH: Humans, 030306 microbiology, MESH: Indinavir, MESH: Models, Biological, MESH: Adult, MESH: Male, MESH: Reverse Transcriptase Inhibitors, [INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM], MESH: Female
Abstract

This work aimed at building a population pharmacokinetic (PK) model for lamivudine (LMV), stavudine (STV) and zidovudine (ZDV), estimating their inter and intraindividual PK variability and investigating the influence of different covariates. Population PK of LMV, STV and ZDV was separately evaluated from plasma concentrations obtained in 54, 39 and 27 HIV1-infected patients, respectively, enrolled in the COPHAR1-ANRS102 trial. The primary objective of this trial was to study the pharmacokinetics of indinavir (IDV) and nelfinavir (NFV) in treated patients with a sustained virological response. Concentrations of nucleoside analogs (NA) were measured in plasma as a secondary objective. A one-compartment model with first-order elimination was used, with zero-order absorption for LMV and first-order absorption for STV and ZDV. Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STV and ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively. For LMV, absorption duration (T a ) was 1.46 h (64%). For STV and ZDV, k a was 0.46 h−1 and 2.9 h−1, respectively. We found a systematic effect of combination with NFV vs. IDV. We found that intrapatient variability was greater than interpatient variability (except for STV) and greater than 55% for the three drugs. This trial enabled the estimation of the population PK parameters of three NA in patients with a sustained virological response, and the median curves could be used as references for concentration-controlled strategies. We observed, as for the protease inhibitors, a great variability of PK parameters.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results